Share price
$3.78
As of Apr 29, 2026
ADCT | NYSE
Adc Therapeutics Sa (ADCT) | runway 18.3 months | financing risk moderate | market cap $479.5M. Daily snapshot of financials, capital pressure, and recent de...
Share price
$3.78
As of Apr 29, 2026
Market cap
$479.5M
Snapshot valuation
30D volume
898,551 shares
Rolling average daily volume
Runway
18.3 months
Estimated from precomputed burn and cash
Financing risk
N/A
Financing risk is present, but the current picture is not yet acute.
Runway: 18.3 months based on estimated burn.
Financing signal: Financing risk is present, but the current picture is not yet acute.
Latest development: ADC Therapeutics SA 424B3 2026-04-15.
424B3 filing submitted on 2026-04-15.
424B3 filing submitted on 2026-03-16.
S-3 filing submitted on 2026-03-10.
10-K filed on 2026-03-10.
8-K filed on 2026-03-10.
Low cash runway companies
Companies screening with the shortest estimated runway based on precomputed burn and cash snapshots.
High burn rate companies
Companies with the highest estimated trailing cash burn across the monitored issuer set.
Recent financing disclosures
Companies with recent financing activity, capital raises, or post-balance-sheet funding events.
Pre-market filings
Companies with recent filings or disclosures posted before the market open.
ADC Therapeutics SA 424B3 2026-04-15
424B3 filing submitted on 2026-04-15.
ADC Therapeutics SA 424B3 2026-03-16
424B3 filing submitted on 2026-03-16.
ADC Therapeutics SA 8-K 2026-03-10
8-K filed on 2026-03-10.
ADC Therapeutics SA 10-K 2026-03-10
10-K filed on 2026-03-10.
Premium analysis
Detailed impact scoring, historical financial trends, full filing analysis, premium alerts, and proprietary signal explanations stay behind login and subscription.